NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
According to recent industrial report, only several products from worldwide NMN manufacturers came close to meeting label claim and contain not enough NMN. Almost products performed better, having at least 88% of the label claim up to small overages. A lone 250 mg product was identified as BRL. In sum, ChromaDex said that 64% of the products tested contained less than 1% of the stated amount of the active ingredient. which should give consumers pause. While this is a limited snapshot of the vast NMN finished product landscape. it does provide a glimpse into the high variability of product quality that is available. The majority of the products may purchase online contain such a small amount of NMN that there would be no clinical benefits achieved from the dose. Another concern with these adulterated products is that the actual contents are not known and could pose a risk to the user the company said in a statement.
NMN powder in general is typically produced via chemical or enzymatic synthesis, or fermentation biosynthesis. There are pros and cons to all three methods.
Chemical synthesis is expensive and labor intensive, and all raw ingredients used are categorized as “unnatural,” i.e., not from biological systems. There are, however, some advantages from the manufacturer’s perspective. The yield is well suited to mass NMN powder production, and all of those unnatural raw ingredients can be carefully controlled. But there are a number of drawbacks as well. Some of the solvents used in the manufacturing process are seriously bad from an environmental standpoint, and impurities and by-products can be challenging to remove from the finished product – that’s seriously bad for the consumer.
Enzymatic production of NMN powder, on the other hand, is considered a “green preparation method.” Like the chemical route, it’s pricey, but it offers a higher yield and impressively high purity. The finished NMN ticks all the boxes – stable, easily absorbed, lightweight, low density, and a low molecular structure.
Fermentation has also been explored as a method of producing NMN, but yield, though high quality, is pretty abysmal, so many supplement companies quite sensibly look to other, more efficacious processes.
1、“Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder
2、Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability of production of NMN powder
3、Industrial leading technology: 15 domestic and international NMN patents
4、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMN powder
5、Multiple in vivo studies show that Bontac NMN powder is safe and effective
6、Provide one-stop product solution customization service
7、NMN raw material supplier of famous David Sinclair team of Harvard University.
1.Raw material production process
Bioenzyme catalysis is a popular production method in the industry. It has a high threshold and several key catalytic enzymes are expensive, accounting for about 80% of the overall production process cost, but it is also the safest and most efficient production method. In the production of NMN by bioenzyme catalysis, the use of food-grade raw materials is an important part of the process to ensure product safety and to ensure that standards are followed.
2.High standard of production conditions
Production conditions refer to the standard of labor consumption required to complete the qualified products of the unit under certain production organization and production technology conditions. There are certifications issued by regulatory authorities, such as cGMP in the United States, TGA in Australia, GMP in Japan, etc.
3.High standard of product testing.
Product testing requires reliable test methods and reagents that are used throughout the production process. They are not only inspection standards for the final product, but also for the intermediate stages of control, including testing of active ingredients, testing of heavy metals such as lead, arsenic and mercury, and testing of pathogenic bacteria, microorganisms and processing by-products.
For NMN products, the commonly used method for active ingredient content testing is high performance liquid chromatography (HPLC), which is efficient, accurate and precise. For different manufacturers, the standards for testing reagents are different. Strict manufacturers will purchase high purity, analytically pure reagents from third party standards companies as controls.
4.Safety assessment
For relatively new raw materials such as NMN, it is not enough for consumers to judge the safety of the product on the side of the merchant alone. At this point, the third-party authoritative assessment report is particularly important.
Currently, there are two generic safety assessment reports, one is a toxicological assessment report and the other is a safety assessment report. In China, toxicological assessment reports usually account for the majority. However, there are still few NMN companies that can issue such reports
5.Storage and Packaging
NMNs are usually stored in sealed containers for up to 12 months. If it can be stored for 24 months with insignificant changes in purity, the stability of NMN is very reliable. Currently, the more common packaging materials are pet or hope, which are pharmaceutical packaging materials. They are non-toxic, odorless, lightweight, portable and effectively isolate air and moisture.
The safety of NMN powder cannot be assessed since required clinical and toxicological studies have not been completed yet to establish the recommended safe levels for long term administration. Nevertheless, their safety and efficacy are uncertain and unreliable since most of them have not been backed up by rigorous scientific preclinical and clinical testing. This issue has been arisen as manufacturers are hesitant to pay for research and clinical trials due to potential lower profit margin, and there is no authorizing agency to regulate NMN products because it is often sold as functional food product rather than heavily regulated therapeutic drug. Therefore, more strict approval process has been demanded by consumer advocacy groups requesting regulatory agencies to set standard and restrictions for marketing anti-aging health products, considering safety, health and wellbeing of consumers. NMN should not be considered as a panacea for the elderly, because boosting NAD levels when not required may yield some detrimental effects. Therefore, the dose and frequency of NMN supplementation should be carefully prescribed depending on the type of age-related deficiency and all other confronting health conditions of the people. Other NAD precursors have been studied to discover the efficacy for diverse age-related deficiencies and they are used for particular deficiencies, only after they are proven for effectiveness and safe to use. Therefore, the same principle should be applied to NMN as well
First, inspect the factory. After some screening, NMN companied that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMN powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMN cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMN powder produced by Bontac reach the purity of 99.9%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
Introduction Wound healing is a sophisticated process responding to tissue damage, which is associated with numbers of interaction of various cell types, cytokines, growth factors, and other molecules. Strikingly, increasing the nicotinamide adenine dinucleotide (NAD) pool by nicotinamide riboside (NR) can accelerate wound healing and macrophage migration, which is partially achieved through PGE2 synthesis and signaling as well as the function of the NAD+-dependent sirtuin, SIRT3. Regulatory effects of NR on the expression of M1 macrophage markers in human MDMs. NR could modulate the expression levels of canonical M1 (inflammatory phenotype) and M2 (reparative phenotype) cell surface markers during macrophage polarization. With a great detail, a significant downregulation in CD64 and a obvious upregulation of CD197/CCR7 are viewed in the polarized M1 cells incubated with NR. Furthermore, NR increases CD197/CCR7-mediated M1 macrophage migration. The significance of chemotaxis mediator PGE2 in NR-regulated macrophage migration NR-mediated upregulation of macrophage migration through CCL19/CCR7 is dependent on the synthesis of PGE2, an inflammatory lipid mediator in the eicosanoid family. Concretely, NR administration increases the PGE2 level in cultured human monocytes, MDMs, and human serum. In addition, NR-mediated increases in CCR7 expression and CCL19-induced migration are attenuated by PGE2 synthesis blockers. NR/SIRT3/migration axis in human M1 MDMs NR facilitates collective cell migration at a SIRT3-dependent manner in human M1 MDMs during wound healing. Simply put, the degree of wound healing is compared on Day 0 and Day 2 in vehicle- or NR-treated human M1 MDMs. It is found that NR increases the relative degree of migration (relative wound healing) and the rate of wound confluence in the presence of CCL19. Besides, the relative degree of wound density (migration) is blunted by SIRT3 knockdown, while being enhanced by SIRT3 overexpression. Application prospect of NR in wound healing Chronic diabetes is often accompanied with poor wound healing. For instance, diabetic foot ulcers, one of the chief cause of amputations, affect 15% of people with diabetes. Given that NR can drive the macrophage migration to boost chronic wound healing, it may have a broad application prospect in treating the wounds including but not limited to diabetic patients. Conclusion In human macrophages, NR induces surface expression of the chemotaxis CD197/CCR7 receptor and levels of its lipid mediator PGE2 via upregulation of cyclooxygenase 2 and functionally increases macrophage migration and wound healing in a SIRT3-dependent manner. Reference Wu J, Bley M, Steans RS, et al. Nicotinamide Riboside Augments Human Macrophage Migration via SIRT3-Mediated Prostaglandin E2 Signaling. Cells. 2024;13(5):455. Published 2024 Mar 5. doi:10.3390/cells13050455 BONTAC NR BONTAC is one of the few suppliers in China that can launch mass production of raw materials for NR, with self-owned factory and professional R&D team. Up till now, there are 173 BONTAC patents. BONTAC provides one-stop service for customized products. Both malate and chloride salt forms of NR are available. By dirt of unique Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method, the product content and conversion rate can be maintained in a higher level. The purity of BONTAC NR can reach above 97%. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
1. Introduction Acute lung injury comprises a uniform response of the lung to inflammatory or chemical insults which is commonly caused by systemic illness including sepsis or trauma, infection with pathogens, and toxic gas inhalation. Sepsis-induced acute lung injury is a leading cause of morbidity and mortality worldwide, imposing substantial economic, social, and health burdens. Despite advances in knowledge of septic pulmonary pathologies over the years, efficient targeted therapies are still lacking. Notably, NMN administration has been uncovered to be effective in alleviating sepsis-induced acute lung injury, which can reduce cellular inflammation, oxidative stress, and apoptosis. 2. The impact of NMN upon macrophage polarization in LPS-induced MH-S cells In mouse alveolar macrophage cell line MH-S treated by lipopolysaccharide (LPS), NMN can facilitate the transformation of macrophages from pro-inflammatory M1 phenotype towards the anti-inflammatory M2 phenotype to promote inflammatory resolution and tissue repair, as evidenced by the downregulation of M1 phenotype-associated markers (iNOS and CD86+ F4/80+) and pro-inflammatory cytokines (IL-1β, TNF-α and IL-6) as well as the upregulation of M2 phenotype-related markers (Arg1 and CD86+ F4/80+) and anti-inflammatory mediators (IL-10) post NMN administration. 3. The alleviation of LPS-induced lung injury post NMN administration In vitro, NMN represses the apoptosis and production of pro-inflammatory factors in LPS-stimulated MH-S cells. In vivo, NMN explicitly ameliorates LPS-induced pathological alterations, encompassing thickened alveolar wall, inflammatory cell infiltration, septa swelling, and erythrocyte exudation, in a murine septic model. 4. The association of SIRT1/NF-κB signaling activation with NMN-mediated macrophage polarization SIRT1/NF-κB signaling pathway is involved in the lung protection of NMN, as manifested by the elevated expression of SIRT1 as well as the reduced acetylation and phosphorylation of NF-κB-p65 post NMN treatment. Repression of SIRT1/NF-κB signaling offsets NMN-mediated M2 macrophage polarization. SIRT1 inhibitor EX-527 decreases the expression of SIRT1, yet increases the expression of acetylated and phosphorylated NF-κB-p65 in septic mice pretreated with NMN. In contrast to NMN, EX-527 overtly promotes the expression levels of M1 macrophage-associated markers (iNOS and CD86) while inhibiting those of M2 phenotype-related markers (Arg1 and CD206). 5. Conclusion NMN can effectively ameliorate LPS-induced acute lung injury through modulating macrophage polarization via SIRT1/NF-κB signalling pathway, providing a novel therapeutic direction for sepsis-induced acute lung injury. 6. Reference He, Simeng et al. “Nicotinamide mononucleotide alleviates endotoxin-induced acute lung injury by modulating macrophage polarization via the SIRT1/NF-κB pathway.” Pharmaceutical biology vol. 62,1 (2024): 22-32. doi:10.1080/13880209.2023.2292256 BONTAC NMN BONTAC is the leader of the global NMN industry, with the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 160 invention patents including 15 NMN patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. Both the high-quality product and excellent service can be better ensured in BONTA. BONTAC has 12 years of industry experience, which is worthy of your trust. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC.
1. Introduction Gastric cancer (GC) represents a global health-care challenge, which is the fifth most common cancer and the fourth leading cause of cancer death across the world in 2020, with a significant incidence rate. Despite the efficacy of improved chemotherapy and surgical options, the prognosis of GC patients remains unsatisfactory. Remarkably, NAD+ is an intriguing target for cancer therapy by leverage of its impacts upon energy metabolism and pathway regulation. This research is engineered to probe into the magic roles of NAD+ metabolism-associated genes (NMRGs) in GC. 2. The establishment of prognostic risk model for GC patients Based on the expression levels of NAD+ metabolism-related genes in GC cell lines, a prognostic model is established for GC patients. Simply put, a total of 13 lncRNAs related to NMRGs are singled out by LASSO regression to construct prognostic risk model, with seven markedly up-regulated lncRNAs and six prominently down-regulated lncRNAs in GC tissues, as confirmed by real-time polymerase chain reaction. On this basis, six lncRNAs with the minimum likelihood of deviance corresponding to the first-rank value of Log (k) are chosen, followed by the plotting of model AUC and calculation of the risk score. The detailed calculation formula is listed below: risk score = AL139147.1 × (0.416) + AC107021.2 × (0.3119) + AC090825.1 × (0.1218) + AC005726.2 × (−0.0.0062) + AC012615.1 × (−0.0130) + AP001107.6 × (−0.0451). It is found that patients with high-risk scores have a poor prognosis. 3. The correlation between immune factors and risk scores The levels of immune cell infiltration, including CD8 T cells, CD4 naïve T cells, CD4 memory-activated T cells, B memory cells, and naïve B cells, are markedly associated with risk scores. Besides, high-risk patients show activated immune checkpoints as well as high immune and stromal scores. 4. The role of NAD+ in the metabolism of GC patients NAD+ not only promotes GC progression, but also promotes immune cell infiltration into tumors. The modulation of NAD+ is significant for the metabolism of GC patients. 5. Conclusion NMRGs may be promising biomarkers for predicting clinical outcomes of GC patients and ultimately facilitating their precise management. Reference Sun, X., Wen, H., Li, F., Bukhari, I., Ren, F., Xue, X., Zheng, P., & Mi, Y. (2023). NAD+ associated genes as potential biomarkers for predicting the prognosis of gastric cancer. Oncology research, 32(2), 283–296. https://doi.org/10.32604/or.2023.044618 BONTAC NAD and NMN BONTAC has rich R&D experience and advanced technology in the biosynthesis of NAD and NMN. Bonzyme whole-enzymatic method is adopted, which is environmental-friendly, with no harmful solvent residues. The purity of products can reach up to 95%, which is benefited from the exclusive Bonpure seven-step purification technology. BONTAC has self-owned factories and has obtained a number of international certifications, where high quality and stable supply of products can be ensured. BONTAC has over 170 domestic and foreign patents, leading the industry of coenzyme and natural products. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.